TMCnet

QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced proposals for its 2026 Annual General Meeting, including plans to appoint co-founder and former Chief Executive Officer Dr. Metin ...
Fintel on MSN

Qiagen NV (QGEN) price target decreased by 13.91% to 46.28

The average one-year price target for Qiagen N.V. (NYSE:QGEN) has been revised to $46.28 / share. This is a decrease of 13.91 ...

Qiagen (NYSE:QGEN) Valuation Check After Extended Share Price Weakness

Recent share performance and business profile Qiagen (QGEN) has drawn attention after a period of weaker share performance, with the stock showing negative returns over the past month, past 3 months, ...
TMCnet

QIAGEN N.V. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

The law firm of Kirby McInerney LLP is investigating potential claims against Qiagen N.V. ("Qiagen" or the "Company") (NYSE:QGEN). The investigation concerns whether the Company a ...

QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to advance its QuantiFERON latent tuberculosis ...

Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bank of America Global Healthcare Conference 2026 May 12, 2026 6:00 PM EDTCompany ParticipantsRoland Sackers - CFO, MD & Member ...
Business Wire

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

Builds on approximately $300 million returned to shareholders in early 2024 as part of commitment to return at least $1 billion through end-2028 VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V.
FierceBiotech

Qiagen turns to Sophia Genetics to squeeze more data from next-gen sequencing tests

Qiagen’s next-generation sequencing tests are already used to look for genetic variants that may shed light on an individual’s specific case of cancer and potential treatment options, but the ...
Nasdaq

QIAGEN Stock Gains Following the Acquisition of Genoox

QIAGEN N.V. QGEN recently signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.
Seeking Alpha

QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028 VENLO, Netherlands-- ...
Nasdaq

QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date

Milestone underlines company’s global leadership in sample preparation Company’s NGS assays also hit milestone of one million samples tested since 2015 New kits and instruments will bolster QIAGEN’s ...
Business Wire

QIAGEN to Enter the DAX – Germany’s Leading Stock Market Index

VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has been chosen to be included in the DAX (Deutscher Aktienindex), the ...